Primary amelanotic malignant melanoma of the parotid gland: a case report.

State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, Chengdu, Sichuan, China.
The Journal of international medical research (Impact Factor: 1.1). 12/2008; 36(6):1435-9. DOI: 10.1177/147323000803600633
Source: PubMed

ABSTRACT Amelanotic malignant melanoma in the oral region is extremely rare and has not previously been reported in the parotid gland. This present case report describes an amelanotic malignant melanoma in the parotid gland, with no other primary lesion detectable. The medical history, pathology and immunohistochemical analysis of the case are described and the relevant literature is reviewed in order to help in the recognition of this uncommon tumour. Amelanotic malignant melanoma is a melanoma subtype with little or no pigmentation and, because of this lack of pigmentation and its wide-ranging clinical appearance, it often defies clinical diagnosis. A high level of vigilance is, therefore, necessary in diagnosing such a tumour in the parotid gland. Where it is suspected, positive expression of S-100 protein and human melanoma black 45(HMB45) using immunohistochemical analysis can be considered reliable methods of confirming diagnosis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: We report a case of primary amelanotic malignant melanoma in the intraglandular lymph node of the parotid gland in a 24 year-old woman. The initial diagnosis was S-100 positive malignant tumour, presumed to be a metastasis of a regressive malignant melanoma although a primary was not found. 15 years later, Melan-A expression and BRAF mutations have been identified in tumour cells, comparable to cutaneous melanomas. 15 years postoperatively the patient is alive and free of disease.The possible origin and the behaviour of the lesion are discussed.
    07/2010; 43(3). DOI:10.1016/j.patol.2010.06.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary malignant melanoma of the esophagus (PMME) is a rare disease that is characterized by aggressive invasion, early metastasis, and poor prognosis. Treatment protocols are not well-established. To understand this condition more precisely, we performed a retrospective review of eight cases of PMME diagnosed at the Thoracic Department of the Cancer Center at Sun Yat-Sen University between 1985 and 2009. Eight PMME patients (five men and three women) with a mean age of 58 years (range: 48 to 72 years) were included. Dysphagia was the most common presenting symptom. All patients underwent an Ivor-Lewis esophagogastrectomy and lymph node dissection with postoperative adjuvant chemotherapy. One patient with stage III/pT4N0M0 underwent postoperative chemotherapy plus radiotherapy. Four patients died of distant metastases. The median survival time was 28 months (range: 11 months to 6 years). Our data confirm that PMME is a highly aggressive disease with a poor prognosis. If the diagnosis is suspected or confirmed as PMME, and the patients have no distal metastases or extensive lymph node enlargement, we suggest that surgery should be the first choice of treatment. With regard to adjuvant therapy, we recommend the addition of chemotherapy. The role of radiotherapy remains questionable and requires further investigation.
    Diseases of the Esophagus 10/2010; 24(2):109-13. DOI:10.1111/j.1442-2050.2010.01111.x · 2.06 Impact Factor


Available from